Daily Respiratory Research Analysis
Three high-impact respiratory studies stood out: a preclinical therapy that targets endothelial calcium signaling to accelerate resolution of lung injury, pharmacologic proof-of-concept that SARS‑CoV‑2 Mac1 is a druggable antiviral target with in vivo survival benefit, and a pragmatic randomized trial showing primary-care pulmonary rehabilitation improves long COVID functional capacity. Together they advance therapeutics, antiviral strategy, and rehabilitation care pathways.
Summary
Three high-impact respiratory studies stood out: a preclinical therapy that targets endothelial calcium signaling to accelerate resolution of lung injury, pharmacologic proof-of-concept that SARS‑CoV‑2 Mac1 is a druggable antiviral target with in vivo survival benefit, and a pragmatic randomized trial showing primary-care pulmonary rehabilitation improves long COVID functional capacity. Together they advance therapeutics, antiviral strategy, and rehabilitation care pathways.
Research Themes
- Endothelial calcium signaling as a therapeutic target in ARDS
- Pharmacological inhibition of SARS-CoV-2 Mac1 to restore innate immunity
- Primary-care pulmonary rehabilitation efficacy in long COVID
Selected Articles
1. Therapeutic targeting of endothelial calcium signaling accelerates the resolution of lung injury.
The authors developed a small-molecule inhibitor of EB3, a microtubule-associated factor that enables pathological IP3R3-mediated calcium signaling in endothelial cells during injury. Pharmacologic targeting of endothelial calcium signaling mitigated the injurious cascade and accelerated resolution of lung injury in preclinical models, highlighting a druggable pathway for ARDS.
Impact: Identifies a previously underexploited endothelial signaling node (EB3/IP3R3) as a tractable target to accelerate lung injury resolution, addressing a major unmet need in ARDS therapeutics.
Clinical Implications: If translated, EB3 inhibition could complement supportive care by directly promoting endothelial barrier recovery and resolution in ARDS, including post-viral lung injury. Early-phase clinical development and biomarker strategies (endothelial Ca2+ signatures) would be key next steps.
Key Findings
- Developed a pharmacological inhibitor targeting EB3, a mediator of pathological endothelial calcium signaling via IP3R3.
- Endothelial calcium signaling inhibition accelerated the resolution of lung injury in preclinical models.
- Positions endothelial EB3/IP3R3 signaling as a druggable pathway for ARDS beyond supportive care.
Methodological Strengths
- Mechanistic target identification and rational inhibitor development.
- Multi-level preclinical validation focused on endothelial signaling biology.
Limitations
- Preclinical evidence; human safety, dosing, and efficacy remain untested.
- Outcome measures in abstract are not quantified; translational biomarkers need definition.
Future Directions: Advance EB3 inhibitors to first-in-human studies with endothelial function biomarkers; explore combination with lung-protective ventilation and anti-inflammatory agents; delineate patient endotypes most likely to benefit.
Acute respiratory distress syndrome (ARDS) is a severe pulmonary disease characterized by acute, noncardiogenic pulmonary edema and hypoxemia leading to respiratory failure. It is induced by a diverse array of etiologies, including recent SARS-CoV-2 infection. The current standard of care for ARDS remains predominantly supportive, underscoring the urgent need for targeted pharmacological interventions. To address this critical gap, we developed an inhibitor of the microtubule accessory factor end-binding protein 3 (EB3), a key mediator of pathological calcium signaling in endothelial cells. During injury, EB3 facilitates inositol 1,4,5-trisphosphate receptor 3 (IP
2. The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2.
AVI‑4206, a potent and selective small‑molecule Mac1 inhibitor, demonstrated high target engagement, strong antiviral effects in human airway organoids and macrophages, and reduced viral load with survival benefit in an in vivo severe SARS‑CoV‑2 model. These data deliver pharmacological proof‑of‑concept that Mac1 is a valid therapeutic target via immune‑restoring mechanisms.
Impact: Provides first pharmacologic validation of coronaviral Mac1 as a drug target with in vivo survival benefit, opening a distinct mechanism that may complement current direct-acting antivirals.
Clinical Implications: Mac1 inhibition may synergize with polymerase/protease inhibitors by restoring innate immunity while suppressing replication, informing combination regimens and next-generation antivirals with reduced resistance risk.
Key Findings
- Identified AVI‑4206 as a potent, selective Mac1 inhibitor with high cellular target engagement.
- Showed stronger antiviral effects in human airway organoids and monocyte-derived macrophages than in standard cell lines.
- Demonstrated reduced viral replication, boosted innate responses, and improved survival in a severe SARS‑CoV‑2 animal model.
Methodological Strengths
- Multi-system validation across cell lines, human airway organoids, primary macrophages, and in vivo models.
- Clear target dependency (Mac1 catalytic activity and IFN-γ dependence) supporting on-target mechanism.
Limitations
- Preclinical stage; human pharmacokinetics, safety, and efficacy are unknown.
- Antiviral potency in standard cell lines was weak, highlighting model-dependent effects.
Future Directions: Advance to Phase 1 trials with pharmacodynamic markers of innate immune restoration; evaluate combinations with direct-acting antivirals; assess breadth against other coronaviral macrodomains.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to pose a threat to public health. Current therapeutics remain limited to direct-acting antivirals that lack distinct mechanisms of action and are already showing signs of viral resistance. The virus encodes an ADP-ribosylhydrolase macrodomain (Mac1) that plays an important role in the coronaviral life cycle by suppressing host innate immune responses. Genetic inactivation of Mac1 abrogates viral replication in vivo by potentiating host innate immune responses. However, it is unknown whether this can be achieved by pharmacologic inhibition and can therefore be exploited therapeutically. Here, we report a potent and selective lead small molecule, AVI-4206, that is effective in an in vivo model of SARS-CoV-2 infection. Standard cellular models indicate that AVI-4206 has high target engagement and can weakly inhibit viral replication in a gamma interferon- and Mac1 catalytic activity-dependent manner. However, a stronger antiviral effect for AVI-4206 is observed in human airway organoids and peripheral blood monocyte-derived macrophages. In an animal model of severe SARS-CoV-2 infection, AVI-4206 reduces viral replication, potentiates innate immune responses, and leads to a survival benefit. Our results provide pharmacological proof of concept that Mac1 is a valid therapeutic target via a novel immune-restoring mechanism that could potentially synergize with existing therapies targeting distinct, essential aspects of the coronaviral life cycle. This approach could be more widely used to target other viral macrodomains to develop antiviral therapeutics beyond COVID-19.
3. Improved functional exercise capacity after primary care pulmonary rehabilitation in patients with long COVID (PuRe-COVID): a pragmatic randomised controlled trial.
In a pragmatic RCT (n=76), a 12‑week, stepwise primary‑care pulmonary rehabilitation program improved 6‑minute walk distance by an estimated +39 m versus control at 12 weeks and reduced fatigue. Odds of clinically significant improvements in 6MWD, fatigue, inspiratory pressure, and dyspnea were higher with PR.
Impact: Delivers randomized evidence that scalable primary‑care pulmonary rehabilitation benefits long COVID, addressing access barriers to hospital‑based programs while demonstrating clinically meaningful functional gains.
Clinical Implications: Primary-care PR can be implemented to improve functional capacity, fatigue, and dyspnea in long COVID; referral pathways and reimbursement models should support community delivery while tailoring to patient tolerance.
Key Findings
- Primary-care pulmonary rehabilitation improved 6MWD by an estimated +39 m at 12 weeks compared with control (p<0.001).
- Significant reductions in fatigue (CIS‑fatigue −6 points) and higher odds of clinically meaningful improvements in dyspnea and inspiratory muscle strength.
- Benefits were observed in a pragmatic, stepwise program suitable for real-world primary-care settings.
Methodological Strengths
- Pragmatic randomized controlled design with clinically relevant endpoints.
- Multiple timepoints and composite functional, symptomatic, and physiologic outcomes.
Limitations
- Modest sample size and single-country setting may limit generalizability.
- Blinding of participants and providers is not feasible in rehabilitation interventions.
Future Directions: Scale-up studies across health systems, evaluation of cost-effectiveness and equity of access, and trials integrating tele-rehabilitation and individualized pacing for post-exertional symptom exacerbation.
BACKGROUND: Pulmonary rehabilitation (PR) improves physical status and symptoms in patients with long COVID, but access to specialised hospital-based centres is challenging. This trial studied the effect of primary care PR on functional exercise capacity and symptoms in patients with long COVID. METHODS: In this pragmatic randomised controlled trial (PuRe-COVID), patients with long COVID were randomised to a 12-week stepwise PR programme in primary care, or to a control group without PR. The primary end point was change in 6 min walk distance (6MWD) from baseline to 12 weeks. Additional outcomes, measured at 6, 12, 24 and 36 weeks, included patient-reported outcomes, physical activity, maximal inspiratory (MIP) and expiratory pressures and hand grip strength. RESULTS: In total, 76 patients were randomised (PR/control group (n=39/37); mean age 49±13 years). The change in 6MWD at 12 weeks was estimated to be +39 m in the PR group compared with the control group (95% CI (18 to 59), p<0.001). Furthermore, a decrease in Checklist Individual Strength (CIS)-fatigue was found for the PR group (-6 points; 95% CI (-10 to -2), p=0.011). At 12 weeks, patients in the intervention group were more likely to have a clinically significant improvement in 6MWD (OR 5.7, 95% CI (2.0 to 16.1), p=0.001), CIS-fatigue (OR 3.8, 95% CI (1.2 to 12.0), p=0.020), MIP (OR 3.7, 95% CI (1.05 to 12.7), p=0.036) and modified Medical Research Council dyspnoea score (OR 5.2, 95% CI (1.6 to 16.4), p=0.003). CONCLUSIONS: Primary care stepwise individual PR may improve functional exercise capacity, fatigue and dyspnoea in patients with long COVID. It therefore may be a promising treatment option in primary care for patients with long COVID experiencing fatigue and/or respiratory symptoms. TRIAL REGISTRATION NUMBER: NCT05244044.